GleamWall
中文EN

QURE uniQure N.V.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1590560 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY28.0%
TTM net income YoY1.0%
TTM EPS YoY20.2%
Revenue 3-yr CAGR-43.5%
Net income 3-yr CAGR—

Margins

Gross margin93.9%
Operating margin-1,001.7%
Net margin-1,154.8%
FCF margin-956.8%
EBITDA margin-921.0%

Returns

ROE-89.0%
ROA-25.5%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets68.7%
Debt / equity0.17x
Current ratio11.52x
Interest coverage-3.51x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue3.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$5.20M$5.84M$3.56M$5.57M$3.70M$5.26M$1.57M$5.22M
Cost of revenue$236,000$350,000$219,000$435,000$398,000$656,000$197,000$619,000
Gross profit$4.96M$5.49M$3.34M$5.13M$3.30M$4.61M$1.37M$4.60M
R&D expense$35.52M$33.96M$29.18M$34.78M$34.37M$35.38M$36.14M$38.84M
SG&A expense$23.92M$17.37M$20.07M$21.61M$19.44M$13.50M$10.91M$11.38M
Operating income-$52.98M-$52.20M-$45.72M-$51.12M-$51.03M-$43.87M-$39.33M-$45.83M
Interest expense$14.58M$14.37M$14.03M$14.57M$16.72M$15.59M$15.11M$14.88M
Pretax income-$60.54M-$79.22M-$53.05M-$41.00M-$71.90M-$37.29M-$43.14M-$72.41M
Income tax$676,000$1.84M$488,000-$3.92M$8.63M$425,000$496,000$856,000
Net income-$61.22M-$81.06M-$53.53M-$37.09M-$80.53M-$37.72M-$43.64M-$73.26M
EBITDA-$47.53M-$47.30M-$42.76M-$48.15M-$47.40M-$40.23M-$34.80M-$44.01M
EPS (basic)-0.88-1.22-0.85—-1.38-0.69-0.82—
EPS (diluted)-0.88-1.22-0.85—-1.38-0.69-0.82—
Weighted avg. shares (diluted)69.90M66.24M62.74M—58.52M54.81M53.11M—
Balance sheet
Cash & equivalents$98.44M$413.03M$139.99M$80.24M$597.06M$253.78M$217.23M$160.33M
Receivables$4.80M$5.78M$3.56M$5.86M————
Current assets$692.54M$834.27M$615.74M$655.99M$716.19M$408.57M$435.42M$390.29M
PP&E, net$9.92M$11.38M$12.01M$13.80M$15.40M$17.49M$18.08M$20.42M
Goodwill$24.50M$24.59M$24.81M$25.36M$25.33M$25.34M$23.35M$22.41M
Intangibles$61.85M$62.10M$69.99M$72.79M$74.14M$75.60M$71.99M$71.04M
Total assets$940.55M$985.10M$778.71M$824.91M$888.38M$584.89M$605.40M$556.54M
Current liabilities$60.14M$83.34M$59.20M$62.92M$100.63M$40.93M$36.31M$40.05M
Long-term debt$50.34M$50.15M$49.94M$49.70M$51.88M$51.84M$51.59M$51.32M
Total debt$50.34M$50.15M$49.94M$49.70M$51.88M$51.84M$51.59M$51.32M
Total liabilities$645.90M$661.05M$629.36M$626.01M$659.64M$588.89M$571.72M$563.29M
Shareholders' equity$294.65M$324.05M$149.34M$198.90M$228.75M-$4.00M$33.69M-$6.75M
Net debt-$48.10M-$362.88M-$90.05M-$30.54M-$545.18M-$201.94M-$165.64M-$109.00M
Shares outstanding70.04M69.33M63.03M62.34M62.17M54.87M54.70M48.99M
Cash flow statement
Operating cash flow-$47.83M-$28.58M-$38.24M-$77.57M-$16.40M-$39.90M-$44.10M-$52.84M
Capital expenditure$11,000$472,000$140,000$119,000-$66,000$260,000$126,000$40,000
Free cash flow-$47.84M-$29.05M-$38.38M-$77.69M-$16.33M-$40.16M-$44.23M-$52.88M
Investing cash flow-$268.73M$53.26M$98.56M-$441.37M$26.58M$73.07M$20.10M-$26.62M
Financing cash flow$1.56M$249.12M$550,000$2.45M$332.24M$44,000$80.67M-$6.52M
Depreciation & amortization$5.45M$4.91M$2.96M$2.97M$3.63M$3.63M$4.53M$1.81M
Stock-based compensation$5.45M$5.02M$5.09M$4.66M$3.52M$5.08M$4.41M$4.75M

Free plan shows the latest 8 periods; Pro shows all 43 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.